Micro Emerging Archived

JNJ Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & Neck Cancer

New narrative with limited coverage — still forming.

Score
0.2
Velocity
▲ 0.0
Articles
1
Sources
1

Sentiment Timeline

Event Timeline

May 31, 2026
J&J Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & … Neutral

Related Articles

J&J Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & Neck Cancer

Nasdaq · May 31, 2026
Mixed

Timeline

Last UpdatedMay 31, 2026